Prevention of HIV and Other Blood-Borne and Sexually Transmitted Diseases in People Who Inject Drugs: Current Status and Future Prospects

  • Richard NeedleEmail author
  • Sasha Mital
  • Andrew Ball


Scientific consensus has emerged that introducing and scaling up core interventions of a comprehensive HIV prevention program—linked with an enabling environment of laws, policies, and regulations supportive of prevention, treatment, and care—can stabilize and halt the spread of, and even reverse, the HIV epidemic among persons who inject drugs (PWID) [1–4]. Yet, the global burden of HIV and other diseases among persons who inject drugs (heroin, cocaine, and amphetamine-type stimulants) is high and growing in many regions of the world. Availability and access to evidence-based core interventions are low; profound obstacles persist, limiting the nature, scope, and quality of prevention, treatment, and care services. Despite the fact that every country reporting persons who inject drugs has made commitments to protect human rights in relation to HIV [5], many do not enforce their policies and violate the human rights of persons who inject drugs [6, 7].


Drug User Harm Reduction Methadone Maintenance Therapy Public Health Approach Syringe Exchange Program 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Wodak A, Cooney A. Effectiveness of sterile needle and syringe programming in reducing HIV/AIDS among injecting drug users. Geneva: World Health Organization; 2005.Google Scholar
  2. 2.
    Needle R, Burrows D, Friedman S, et al. Effectiveness of community-based outreach in preventing HIV/AIDS among injection drug users. Geneva: World Health Organization; 2004.Google Scholar
  3. 3.
    Farrell M, Marsden J, Ling W, Ali R, Gowing L. Effectiveness of drug dependence treatment in preventing HIV among injecting drug users. Geneva: World Health Organization; 2005.Google Scholar
  4. 4.
    Piot P, Zewdie D, Turmen T. HIV/AIDS prevention and treatment. Lancet. 2002;360(9326):86–8.PubMedCrossRefGoogle Scholar
  5. 5.
    UNGASS. Declaration of commitment on HIV/AIDS. New York: United Nations; 2001.Google Scholar
  6. 6.
    UNAIDS. Call for urgent action to improve coverage of HIV services for injecting drug users. UNAIDS 2010 March 10; Available from:
  7. 7.
    Jurgens R, Ball A, Verster A. Interventions to reduce HIV transmission related to injecting drug use in prison. Lancet Infect Dis. 2009;9(1):57–66.PubMedCrossRefGoogle Scholar
  8. 8.
    Mathers BM, Degenhardt L, Phillips B, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. 2008;372(9651):1733–45.PubMedCrossRefGoogle Scholar
  9. 9.
    Gordon RJ, Lowy FD. Bacterial infections in drug users. N Engl J Med. 2005;353(18):1945–54.PubMedCrossRefGoogle Scholar
  10. 10.
    Hoffmann CJ, Thio CL. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis. 2007;7(6):402–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Roy KM, Goldberg DJ, Hutchinson S, et al. Hepatitis C virus among self declared non-injecting sexual partners of injecting drug users. J Med Virol. 2004;74:62–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Centers for Disease Control and Prevention. Surveillance for acute viral hepatitis—United States, 2006. MMWR Recomm Rep. 2008;57(SS-2):1–24.Google Scholar
  13. 13.
    Urbanus AT, van de Laar TJ, Stolte IG, et al. Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic. AIDS. 2009;23(12):F1–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Danta M, Brown D, Bhagani S, et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS. 2007;21(8):983–91.PubMedCrossRefGoogle Scholar
  15. 15.
    Des Jarlais C, Semaan S. HIV and other sexually transmitted infections in injection drug users and crack cocaine smokers. In: Holmes KK, Sparling PF, Stamm WE, Piot P, Wasserheit JN, Corey L, et al., editors. Sexually transmitted diseases. 4th ed. New York: McGraw-Hill; 2008. p. 237–55.Google Scholar
  16. 16.
    Needle R, Zhao L. HIV prevention among injection drug users: closing the coverage GAP. Washington, DC: Center for Strategic and International Studies Global Health Policy Center; 2010.Google Scholar
  17. 17.
    Mathers BM, Degenhardt L, Ali H, et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet. 2010;375(9719): 1014–28.PubMedCrossRefGoogle Scholar
  18. 18.
    Mathers BM, Degenhardt L, Adam P, et al. Estimating the level of HIV prevention coverage, knowledge and protective behavior among injecting drug users: what does the 2008 UNGASS reporting round tell us? J Acquir Immune Defic Syndr. 2009;52 Suppl 2:S132–42.PubMedCrossRefGoogle Scholar
  19. 19.
    Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, Hickman M. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet. 2010;376(9737):285–301.PubMedCrossRefGoogle Scholar
  20. 20.
    Gostin LO, Lazzarini Z. Prevention of HIV/AIDS among injection drug users: the theory and science of public health and criminal justice approaches to disease prevention. Emory Law J. 1997;46(2):587–696.PubMedGoogle Scholar
  21. 21.
    Jurgens R, Csete J, Amon JJ, Baral S, Beyrer C. People who use drugs, HIV, and human rights. Lancet. 2010;376(9739):475–85.PubMedCrossRefGoogle Scholar
  22. 22.
    UNODC. World Drug Report. New York: United Nations; 2008.Google Scholar
  23. 23.
    International HIV/AIDS Alliance. Global commission on HIV and the law. International HIV/AIDS Alliance 2010. Available from:
  24. 24.
    International HIV/AIDS Alliance, Commonwealth HIV and AIDS Action Group. Enabling legal environments for effective HIV responses: a leadership challenge for the Commonwealth. 2010.Google Scholar
  25. 25.
    UNAIDS. Report on the Global AIDS Epidemic. Geneva: World Health Organization; 2010.Google Scholar
  26. 26.
    Beyrer C, Razak MH, Lisam K, Chen J, Lui W, Yu XF. Overland heroin trafficking routes and HIV-1 spread in south and south-east Asia. AIDS. 2000;14(1):75–83.PubMedCrossRefGoogle Scholar
  27. 27.
    UNODC. World Drug Report. New York: United Nations; 2010.Google Scholar
  28. 28.
    Ditton J, Frischer M. Computerized projection of future heroin epidemics: a necessity for the 21st century? Subst Use Misuse. 2001;36(1–2):151–66.PubMedCrossRefGoogle Scholar
  29. 29.
    Hughes PH, Rieche O. Heroin epidemics revisited. Epidemiol Rev. 1995;17(1):66–73.PubMedGoogle Scholar
  30. 30.
    Substance Abuse and Mental Health Services Administration. Results from the 2009 National Survey on Drug Use and Health: National Findings. Rockville, MD: US Department of Health and Human Services; 2010. Report No.: Publication No. SMA 10-4586.Google Scholar
  31. 31.
    Wiessing L, Likatavicius G, Klempova D, Hedrich D, Nardone A, Griffiths P. Associations between availability and coverage of HIV-prevention measures and subsequent incidence of diagnosed HIV infection among injection drug users. Am J Public Health. 2009;99(6):1049–52.PubMedCrossRefGoogle Scholar
  32. 32.
    Substance Abuse and Mental Health Services Administration OoAS. Treatment Episode Data Set (TEDS). Highlights—2007. National Admissions to Substance Abuse Treatment Services. Rockville, MD, Department of Health and Human Services; 2009. Report No.: DHHS Publication No. (SMA) 09-4360.Google Scholar
  33. 33.
    U.S. Census Bureau. State and County QuickFacts: Data derived from Population Estimates. httt:// 2009. Available from:
  34. 34.
    Centers for Disease Control and Prevention. Sexually transmitted disease surveillance, 2007. Atlanta, GA: Department of Health and Human Services; 2008.Google Scholar
  35. 35.
    Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 2007. Atlanta, GA: U.S. Department of Health and Human Services; 2009.Google Scholar
  36. 36.
    Centers for Disease Control and Prevention. HIV infections among injection-drug users—34 states, 2004–2007. MMWR Recomm Rep. 2009;58(46): 1291–5.Google Scholar
  37. 37.
    Centers for Disease Control and Prevention. Surveillance for acute viral hepatitis—United States 2007. MMWR Recomm Rep 2009;58:1–37.Google Scholar
  38. 38.
    Ball AL, Rana S, Dehne KL. HIV prevention among injecting drug users in developing and transitional countries. Pub Health Rep 1998; 113(Supp 1) 170–81.Google Scholar
  39. 39.
    Des Jarlais DC, Friedman SR, Novick DM, et al. HIV-1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987. JAMA. 1989;261(7):1008–12.PubMedCrossRefGoogle Scholar
  40. 40.
    Wolfe D, Malinowska-Sempreuch K. Illicit drug policies and the global HIV epidemic: Effects of UN and national government approaches. New York: Open Society Institute; 2004.Google Scholar
  41. 41.
    Needle RH, Kroeger K, Belani H, Hegle J. Substance abuse and HIV in sub-Saharan Africa: introduction to the special issue. Afr J Drug Alcohol Stud. 2006;5(2):83–91.Google Scholar
  42. 42.
    Beckerleg S, Telfer M, Hundt GL. The rise of injecting drug use in East Africa: a case study from Kenya. Harm Reduct J. 2005;2:12.PubMedCrossRefGoogle Scholar
  43. 43.
    Parry CD, Pithey AL. Risk behaviour and HIV among drug using populations in South Africa. Afr J Drug Alcohol Stud. 2006;5(2):140–57.Google Scholar
  44. 44.
    Centers for Disease Control and Prevention. HIV-associated behaviors among injecting-drug users—23 cities, United States, May 2005–February 2006. MMWR Recomm Rep. 2009;58(13):329–32.Google Scholar
  45. 45.
    Strathdee SA, Sherman SG. The role of sexual ­transmission of HIV infection among injection and non-injection drug users. J Urban Health. 2003;80(4 Suppl 3):iii7–14.PubMedGoogle Scholar
  46. 46.
    Des Jarlais DC, Arasteh K, Semaan S, Wood E. HIV among injecting drug users: current epidemiology, biologic markers, respondent-driven sampling, and supervised-injection facilities. Curr Opin HIV AIDS. 2009;4(4):308–13.PubMedCrossRefGoogle Scholar
  47. 47.
    Centers for Disease Control and Prevention. Diagnoses of HIV infection and AIDS in the United States and dependent areas, 2008. Atlanta, GA: Department of Health and Human Services; 2011.Google Scholar
  48. 48.
    Thorpe LE, Outlett LJ, Hershow R, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol. 2002;15:645–53.CrossRefGoogle Scholar
  49. 49.
    Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5(9):558–67.PubMedCrossRefGoogle Scholar
  50. 50.
    Simonsen L, Kane A, Zaffran M, Kane M. Unsafe injections in the developing world and transmission of blood-borne pathogens: a review. Bull World Health Organ. 1999;77(10):789–801.PubMedGoogle Scholar
  51. 51.
    Crofts N, Nigro L, Oman K, Stevenson E, Sherman J. Methadone maintenance and hepatitis C virus infection among injecting drug users. Addiction. 1997;92(8):999–1005.PubMedCrossRefGoogle Scholar
  52. 52.
    Centers for Disease Control and Prevention. Sexually transmitted disease treatment guidelines, 2010. MMWR Recomm Rep. 2010;59(12):1–10.Google Scholar
  53. 53.
    van de Laar TJ, van der Bij AK, Prins M, et al. Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J Infect Dis. 2007;196(2):230–8.PubMedCrossRefGoogle Scholar
  54. 54.
    Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis. 2009;49(4):561–73.PubMedCrossRefGoogle Scholar
  55. 55.
    International Harm Reduction Association. The Global State of Harm Reduction 2010: Key issues for broadening the response. London: International Harm Reduction Association; 2010.Google Scholar
  56. 56.
    Aceijas C, Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy. 2007;18(5):352–8.PubMedCrossRefGoogle Scholar
  57. 57.
    Aceijas C, Stimson GV, Hickman M, Rhodes T. Global overview of injecting drug use and HIV infection among injecting drug users. AIDS. 2004;18(17):2295–303.PubMedCrossRefGoogle Scholar
  58. 58.
    Murrill CS, Weeks H, Castrucci BC, et al. Age-specific seroprevalence of HIV, hepatitis B virus, and hepatitis C virus infection among injection drug users admitted to drug treatment in 6 US cities. Am J Public Health. 2002;92(3):385–7.PubMedCrossRefGoogle Scholar
  59. 59.
    Craine N, Walker AM, Williamson S, Brown A, Hope VD. Hepatitis B and hepatitis C seroprevalence and risk behaviour among community-recruited drug injectors in North West Wales. Commun Dis Public Health. 2004;7(3):216–9.PubMedGoogle Scholar
  60. 60.
    Shapatava E, Nelson KE, Tsertsvadze T, del Rio C. Risk behaviors and HIV, hepatitis B, and hepatitis C seroprevalence among injection drug users in Georgia. Drug Alcohol Depend. 2006;82 Suppl 1:S35–8.PubMedCrossRefGoogle Scholar
  61. 61.
    Gerlich M, Gschwend P, Uchtenhagen A, Kramer A, Rehm J. Prevalence of hepatitis and HIV infections and vaccination rates in patients entering the heroin-assisted treatment in Switzerland between 1994 and 2002. Eur J Epidemiol. 2006;21(7):545–9.PubMedCrossRefGoogle Scholar
  62. 62.
    Centers for Disease Control and Prevention. Coinfection with HIV and Hepatitis C Virus. Centers for Disease Control and Prevention 2005;Available at URL:
  63. 63.
    Semaan S, Des J, Malow R. STDs among Illicit Drug Users in the United States: The need for interventions. In: Aral SO, Douglas JM, editors. Behavioral Interventions for Prevention and Control of Sexually Transmitted Diseases. New York: Springer Science Business Media, LLC; 2007. p. 397–430.CrossRefGoogle Scholar
  64. 64.
    Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2009. Atlanta, GA: Department of Health and Human Services; 2010.Google Scholar
  65. 65.
    Coffin LS, Newberry A, Hagan H, Cleland CM, Des J, Perlman DC. Syphilis in drug users in low and middle income countries. Int J Drug Policy. 2010;21:20–7.PubMedCrossRefGoogle Scholar
  66. 66.
    Platt L, Rhodes T, Judd A, et al. Effects of sex work on the prevalence of syphilis among injection drug users in 3 Russian cities. Am J Public Health. 2007;97(3):478–85.PubMedCrossRefGoogle Scholar
  67. 67.
    Altaf A, Shah SA, Zaidi NA, Memon A, Nadeem uR, Wray N. High risk behaviors of injection drug users registered with harm reduction programme in Karachi, Pakistan. Harm Reduct J. 2007;4:7.PubMedCrossRefGoogle Scholar
  68. 68.
    Rhodes T, Platt L, Maximova S, et al. Prevalence of HIV, hepatitis C and syphilis among injecting drug users in Russia: a multi-city study. Addiction. 2006;101(2):252–66.PubMedCrossRefGoogle Scholar
  69. 69.
    Carey MP, Ravi V, Chandra PS, Desai A, Neal DJ. Screening for sexually transmitted infections at a DeAddictions service in south India. Drug Alcohol Depend. 2006;82(2):127–34.PubMedCrossRefGoogle Scholar
  70. 70.
    Rawson RA, Washton A, Domier CP, Reiber C. Drugs and sexual effects: role of drug type and gender. J Subst Abuse Treat. 2002;22(2):103–8.PubMedCrossRefGoogle Scholar
  71. 71.
    Ross L, Kohler CL, Grimley DM, Bellis J. Intention to use condoms among three low-income, urban African American subgroups: cocaine users, noncocaine drug users, and non-drug users. J Urban Health. 2003;80(1):147–60.PubMedCrossRefGoogle Scholar
  72. 72.
    Booth RE, Watters JK, Chitwood DD. HIV risk-related sex behaviors among injection drug users, crack smokers, and injection drug users who smoke crack. Am J Public Health. 1993;83(8):1144–8.PubMedCrossRefGoogle Scholar
  73. 73.
    Reback CJ, Larkins S, Shoptaw S. Changes in the meaning of sexual risk behaviors among gay and bisexual male methamphetamine abusers before and after drug treatment. AIDS Behav. 2004;8(1): 87–98.PubMedCrossRefGoogle Scholar
  74. 74.
    Shoptaw S, Reback CJ. Methamphetamine use and infectious disease-related behaviors in men who have sex with men: implications for interventions. Addiction. 2007;102 Suppl 1:130–5.PubMedCrossRefGoogle Scholar
  75. 75.
    Semple SJ, Zians J, Grant I, Patterson TL. Impulsivity and methamphetamine use. J Subst Abuse Treat. 2005;29(2):85–93.PubMedCrossRefGoogle Scholar
  76. 76.
    Donoghoe MC. Sex, HIV and the injecting drug users. Br J Addict. 1992;87(3):405–16.PubMedCrossRefGoogle Scholar
  77. 77.
    Edlin BR, Irwin KL, Faruque S, et al. Intersecting epidemics–crack cocaine use and HIV infection among inner-city young adults. Multicenter Crack Cocaine and HIV Infection Study Team. N Engl J Med. 1994;331(21):1422–7.PubMedCrossRefGoogle Scholar
  78. 78.
    Tross S, Abdul-Quader A, Silvert H, Des J. Condom use among male injecting-drug users—New York City, 1987–1990. MMWR Recomm Rep. 1992; 41(34):617–20.Google Scholar
  79. 79.
    Greenberg J, Schnell D, Conlon R. Behaviors of crack cocaine users and their impact on early syphilis intervention. Sex Transm Dis. 1992;19(6): 346–50.PubMedCrossRefGoogle Scholar
  80. 80.
    UNODC. World Drug Report. New York: United Nations; 2005.Google Scholar
  81. 81.
    Aral SO. Determinants of STD epidemics: implications for phase appropriate intervention strategies. Sex Transm Infect. 2002;78 Suppl 1:i3–13.PubMedCrossRefGoogle Scholar
  82. 82.
    Cochran SD, Ackerman D, Mays VM, Ross MW. Prevalence of non-medical drug use and dependence among homosexually active men and women in the US population. Addiction. 2004;99(8):989–98.PubMedCrossRefGoogle Scholar
  83. 83.
    Celentano DD, Valleroy LA, Sifakis F, et al. Associations between substance use and sexual risk among very young men who have sex with men. Sex Transm Dis. 2006;33(4):265–71.PubMedGoogle Scholar
  84. 84.
    Bolding G, Hart G, Sherr L, Elford J. Use of crystal methamphetamine among gay men in London. Addiction. 2006;101(11):1622–30.PubMedCrossRefGoogle Scholar
  85. 85.
    Colfax GN, Mansergh G, Guzman R, et al. Drug use and sexual risk behavior among gay and bisexual men who attend circuit parties: a venue-based comparison. J Acquir Immune Defic Syndr. 2001;28(4):373–9.PubMedGoogle Scholar
  86. 86.
    Colfax G, Santos GM, Chu P, et al. Amphetamine-group substances and HIV. Lancet. 2010;376(9739):458–74.PubMedCrossRefGoogle Scholar
  87. 87.
    Semple SJ, Zians J, Strathdee SA, Patterson TL. Sexual marathons and methamphetamine use among HIV-positive men who have sex with men. Arch Sex Behav. 2009;38(4):583–90.PubMedCrossRefGoogle Scholar
  88. 88.
    Wong W, Chaw JK, Kent CK, Klausner JD. Risk factors for early syphilis among gay and bisexual men seen in an STD clinic: San Francisco, 2002–2003. Sex Transm Dis. 2005;32(7):458–63.PubMedCrossRefGoogle Scholar
  89. 89.
    Weber MP, Schoenbaum EE. Heterosexual transmission of HIV infection in intravenous and non-intravenous drug-using populations. Arch AIDS Res. 1991;5:45–7.Google Scholar
  90. 90.
    Stockman JK, Strathdee SA. HIV among people who use drugs: a global perspective of populations at risk. J Acquir Immune Defic Syndr. 2010;55 Suppl 1:S17–22.PubMedCrossRefGoogle Scholar
  91. 91.
    Gollub EL. A neglected population: drug-using women and women’s methods of HIV/STI prevention. AIDS Educ Prev. 2008;20(2):107–20.PubMedCrossRefGoogle Scholar
  92. 92.
    Marx R, Aral SO, Rolfs RT, Sterk CE, Kahn JG. Crack, sex, and STD. Sex Transm Dis. 1991;18(2):92–101.PubMedCrossRefGoogle Scholar
  93. 93.
    CDC. Relationship of syphilis to drug use and prostitution—Connecticut and Philadelphia, Pennsylvania. Morb Mortal Wkly Rep. 1988;37(49):755–8.Google Scholar
  94. 94.
    Williams PB, Ekundayo O. Study of distribution and factors affecting syphilis epidemic among inner-city minorities of Baltimore. Public Health. 2001;115(6):387–93.PubMedCrossRefGoogle Scholar
  95. 95.
    Ross MW, Hwang LY, Zack C, Bull L, Williams ML. Sexual risk behaviours and STIs in drug abuse treatment populations whose drug of choice is crack cocaine. Int J STD AIDS. 2002;13(11):769–74.PubMedCrossRefGoogle Scholar
  96. 96.
    Baseman J, Ross M, Williams M. Sale of sex for drugs and drugs for sex: an economic context of sexual risk behavior for STDs. Sex Transm Dis. 1999;26(8):444–9.PubMedCrossRefGoogle Scholar
  97. 97.
    Rhodes T, Singer M, Bourgois P, Friedman SR, Strathdee SA. The social structural production of HIV risk among injecting drug users. Soc Sci Med. 2005;61(5):1026–44.PubMedCrossRefGoogle Scholar
  98. 98.
    Rhodes T, Simic M. Transition and the HIV risk environment. BMJ. 2005;331(7510):220–3.PubMedCrossRefGoogle Scholar
  99. 99.
    Gupta GR, Parkhurst JO, Ogden JA, Aggleton P, Mahal A. Structural approaches to HIV prevention. Lancet. 2008;372(9640):764–75.PubMedCrossRefGoogle Scholar
  100. 100.
    National Council Against Addictions, National Institute on Psychiatry Ramon de la Fuente, National Institute on Public Health. 2008 National Household Survey on Addictions, Mexico. 2009.Google Scholar
  101. 101.
    Todd CS, Safi N, Strathdee SA. Drug use and harm reduction in Afghanistan. Harm Reduct J. 2005;2:13.PubMedCrossRefGoogle Scholar
  102. 102.
    Fallahzadeh H, Morowatisharifabad M, Ehrampoosh MH. HIV/AIDS epidemic features and trends in Iran, 1986–2006. AIDS Behav. 2009;13(2): 297–302.PubMedCrossRefGoogle Scholar
  103. 103.
    Needle R, Kroeger K, Belani H, Achrekar A, Parry CD, Dewing S. Sex, drugs, and HIV: rapid assessment of HIV risk behaviors among street-based drug using sex workers in Durban, South Africa. Soc Sci Med. 2008;67(9):1447–55.PubMedCrossRefGoogle Scholar
  104. 104.
    Parry CD, Carney T, Petersen P, Dewing S, Needle R. HIV-risk behavior among injecting or non-injecting drug users in Cape Town, Pretoria, and Durban, South Africa. Subst Use Misuse. 2009;44(6):886–904.PubMedCrossRefGoogle Scholar
  105. 105.
    Reid SR. Injection drug use, unsafe medical injections, and HIV in Africa: a systematic review. Harm Reduct J. 2009;6:24.PubMedCrossRefGoogle Scholar
  106. 106.
    Gable L, Gamhartner K, Gostin LO, Hodge JG, van Puymbroeck RV. Legal aspects of HIV/AIDS: a guide for policy and law reform. Washington, DC: The World Bank; 2007.CrossRefGoogle Scholar
  107. 107.
    Wolfe D, Cohen J. Human rights and HIV prevention, treatment, and care for people who inject drugs: key principles and research needs. J Acquir Immune Defic Syndr. 2010;55 Suppl 1:S56–62.PubMedCrossRefGoogle Scholar
  108. 108.
    Strathdee SA, Hallett TB, Bobrova N, et al. HIV and risk environment for injecting drug users: the past, present, and future. Lancet. 2010;376(9737): 268–84.PubMedCrossRefGoogle Scholar
  109. 109.
    Clark PA, Fadus M. Federal funding for needle exchange programs. Med Sci Monit. 2010;16(1): H1–13.Google Scholar
  110. 110.
    Kamarulzaman A. Impact of HIV prevention programs on drug users in Malaysia. J Acquir Immune Defic Syndr. 2009;52 Suppl 1:S17–9.PubMedCrossRefGoogle Scholar
  111. 111.
    Fields G. While house czar calls for end to ‘war on drugs’. Wall Street Journal 2009 May 14.Google Scholar
  112. 112.
    Macalino GE, Vlahov D, Sanford-Colby S, et al. Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons. Am J Public Health. 2004;94(7):1218–23.PubMedCrossRefGoogle Scholar
  113. 113.
    Jurgens R, World Health Organization, UNODC, UNIADS. Interventions to address HIV in prisons: HIV care, treatment and support. Geneva: World Health Organization; 2007.Google Scholar
  114. 114.
    Okie S. Sex, drugs, prisons, and HIV. N Engl J Med. 2007;356(2):105–8.PubMedCrossRefGoogle Scholar
  115. 115.
    Johnson RC, Raphael S. The effects of male incarceration dynamics on acquired immune deficiency syndrome infection rates among African American women and men. J Law Economics. 2009;52(May):251–93.CrossRefGoogle Scholar
  116. 116.
    Sabol WJ, Couture H. Prison inmates at midyear 2007. Washington, DC: Department of Justice Bureau of Justice Statistics; 2008.Google Scholar
  117. 117.
    Mauer M. Racial disparities in the criminal justice system. Washington, DC: The Sentencing Project; 2009.Google Scholar
  118. 118.
    U.S. Sentencing Commission. Sourcebook of federal sentencing statistics, Tables 33-36 and Table 38. U S Sentencing Commission 2009;Available at: URL:,,,,
  119. 119.
    Bureau of Justice Statistics. Drug use and dependence, state and federal prisoners, 2004. Washington, DC: U.S. Department of Justice; 2006. Report No.: NCJ 213530.Google Scholar
  120. 120.
    Werb D, Kerr T, Small W, Li K, Montaner J, Wood E. HIV risks associated with incarceration among injection drug users: implications for prison-based public health strategies. J Public Health (Oxf). 2008;30(2):126–32.CrossRefGoogle Scholar
  121. 121.
    Milloy MJ, Buxton J, Wood E, Li K, Montaner JS, Kerr T. Elevated HIV risk behaviour among recently incarcerated injection drug users in a Canadian setting: a longitudinal analysis. BMC Public Health. 2009;9:156.PubMedCrossRefGoogle Scholar
  122. 122.
    Clarke JG, Stein MD, Hanna L, Sobota M, Rich JD. Active and Former Injection Drug Users Report of HIV Risk Behaviors During Periods of Incarceration. Subst Abus. 2001;22(4):209–16.PubMedGoogle Scholar
  123. 123.
    UNAIDS Reference Group on HIV and Human Rights. Statement on Human Rights and Universal Access to HIV, Prevention, Treatment, Care & Support. 2008.Google Scholar
  124. 124.
    Wechsberg WM, Luseno W, Ellerson RM. Reaching women substance abusers in diverse settings: stigma and access to treatment 30 years later. Subst Use Misuse. 2008;43(8–9):1277–9.PubMedCrossRefGoogle Scholar
  125. 125.
    UNODC. HIV/AIDS prevention and care for female injecting drug users. Austria: UNODC; 2006.Google Scholar
  126. 126.
    Cleland CM, Des J, Perlis TE, Stimson G, Poznyak V. HIV risk behaviors among female IDUs in developing and transitional countries. BMC Public Health. 2007;7:271.PubMedCrossRefGoogle Scholar
  127. 127.
    Bryant J, Brener L, Hull P, Treloar C. Needle sharing in regular sexual relationships: an examination of serodiscordance, drug using practices, and the gendered character of injecting. Drug Alcohol Depend. 2010;107(2–3):182–7.PubMedCrossRefGoogle Scholar
  128. 128.
    el-Bassel N, Gilbert L, Wu E, Go H, Hill J. HIV and intimate partner violence among methadone-maintained women in New York City. Soc Sci Med. 2005;61(1):171–83.PubMedCrossRefGoogle Scholar
  129. 129.
    el-Bassel N, Terlikbaeva A, Pinkham S. HIV and women who use drugs: double neglect, double risk. Lancet. 2010;376(9738):312–4.PubMedCrossRefGoogle Scholar
  130. 130.
    el-Bassel N, Gilbert L, Wu E, Go H, Hill J. Relationship between drug abuse and intimate partner violence: a longitudinal study among women receiving methadone. Am J Public Health. 2005;95(3):465–70.PubMedCrossRefGoogle Scholar
  131. 131.
    Kumar MS, Virk HK, Chaudhuri A, Mittal A, Lewis G. A rapid situation and response assessment of the female regular sex partners of male drug users in South Asia: factors associated with condom use during the last sexual intercourse. Int J Drug Policy. 2008;19(2):148–58.PubMedCrossRefGoogle Scholar
  132. 132.
    Pinkham S, Malinowska-Sempruch K. Women, harm reduction and HIV. Reprod Health Matters. 2008;16(31):168–81.PubMedCrossRefGoogle Scholar
  133. 133.
    Carael M, Marais H, Polsky J, Mendoza A. Is there a gender gap in the HIV response? Evaluating national HIV responses from the United Nations General Assembly Special Session on HIV/AIDS country reports. J Acquir Immune Defic Syndr. 2009;52 Suppl 2:S111–8.PubMedCrossRefGoogle Scholar
  134. 134.
    Dolan K, Salimi S, Nassirimanesh B, Mohsenifar S, Mokri A. The establishment of a methadone treatment clinic for women in Tehran, Iran. J Public Health Policy. 2011;32:219–30.PubMedCrossRefGoogle Scholar
  135. 135.
    Ball AL. HIV, injecting drug use and harm reduction: a public health response. Addiction. 2007;102(5):684–90.PubMedCrossRefGoogle Scholar
  136. 136.
    Des Jarlais DC, Semaan S. HIV prevention for injecting drug users: the first 25 years and counting. Psychosom Med. 2008;70(5):606–11.PubMedCrossRefGoogle Scholar
  137. 137.
    Hartel DM, Schoenbaum EE. Methadone treatment protects against HIV infection: two decades of experience in the Bronx, New York City. Public Health Rep. 1998;113 Suppl 1:107–15.PubMedGoogle Scholar
  138. 138.
    Coyle SL, Needle RH, Normand J. Outreach-based HIV prevention for injecting drug users: a review of published outcome data. Public Health Rep. 1998;113 Suppl 1:19–30.PubMedGoogle Scholar
  139. 139.
    Preventing HIV transmission: The role of sterile needles and bleach. Washington, DC: National Academy Press; 1995Google Scholar
  140. 140.
    Institute of Medicine. Preventing HIV transmission: The role of sterile needles. Institute of Medicine: National Academy Press; 1994.Google Scholar
  141. 141.
    Dole VP, Nyswander M. A medical treatment for diacetylmorphine (Heroin) addiction. A clinical trial with methadone hydrochloride. JAMA. 1965;193:646–50.PubMedCrossRefGoogle Scholar
  142. 142.
    Institute of Medicine. Preventing HIV Infection among Injecting Drug Users in High-Risk Countries. Washington, DC: The National Academies Press; 2007.Google Scholar
  143. 143.
    Metzger DS, Navaline H, Woody GE. Drug abuse treatment as AIDS prevention. Public Health Rep. 1998;113 Suppl 1:97–106.PubMedGoogle Scholar
  144. 144.
    Walsh N, Higgs P, Crofts N. Recognition of hepatitis C virus coinfection in HIV-positive injecting drug users in Asia. J Acquir Immune Defic Syndr. 2007;45(3):363–5.PubMedCrossRefGoogle Scholar
  145. 145.
    Hagan H, Jarlais DC, Friedman SR, Purchase D, Alter MJ. Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program. Am J Public Health. 1995;85(11):1531–7.PubMedCrossRefGoogle Scholar
  146. 146.
    Thiede H, Hagan H, Murrill CS. Methadone treatment and HIV and hepatitis B and C risk reduction among injectors in the Seattle area. J Urban Health. 2000;77(3):331–45.PubMedCrossRefGoogle Scholar
  147. 147.
    Substance Abuse and Mental Health Services Administration OoAS. The NSDUH report: Methamphetamine use, abuse, and dependence: 2002, 2003, and 2004. Washington, DC: Substance Abuse and Mental Health Services Administration; 2005.Google Scholar
  148. 148.
    Magura S, Kang SY, Nwakeze PC, Demsky S. Temporal patterns of heroin and cocaine use among methadone patients. Subst Use Misuse. 1998;33(12): 2441–67.PubMedCrossRefGoogle Scholar
  149. 149.
    Thula MA. Cocaine use and dependence in clients attending a drug treatment centre in Dublin. The Psychiatrist. 2009;33:88–91.Google Scholar
  150. 150.
    Dutra L, Stathopoulou G, Basden SL, Leyro TM, Powers MB, Otto MW. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry. 2008;165(2):179–87.PubMedCrossRefGoogle Scholar
  151. 151.
    Lee NK, Rawson RA. A systematic review of cognitive and behavioural therapies for methamphetamine dependence. Drug Alcohol Rev. 2008;27(3):309–17.PubMedCrossRefGoogle Scholar
  152. 152.
    Oliveto A, Poling J, Mancino MJ, et al. Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. Drug Alcohol Depend. 2011;113(2–3):184–91.PubMedCrossRefGoogle Scholar
  153. 153.
    Kuehn BM. Scientists target cocaine addiction. JAMA. 2009;302(24):2641–2.PubMedCrossRefGoogle Scholar
  154. 154.
    Nelles J, Fuhrer A, Hirsbrunner H, Harding T. Provision of syringes: the cutting edge of harm reduction in prison? BMJ. 1998;317(7153):270–3.PubMedCrossRefGoogle Scholar
  155. 155.
    Stark K, Herrmann U, Ehrhardt S, Bienzle U. A syringe exchange programme in prison as prevention strategy against HIV infection and hepatitis B and C in Berlin, Germany. Epidemiol Infect. 2006;134(4):814–9.PubMedCrossRefGoogle Scholar
  156. 156.
    Menoyo C, Zulaica D, Parras F. Needle exchange programs in prisons in Spain. Can HIV AIDS Policy Law Rev. 2000;5(4):20–1.PubMedGoogle Scholar
  157. 157.
    Stover H. Evaluation of needle exchange pilot projects shows positive results. Can HIV AIDS Policy Law Newsl. 2000;5(2–3):60–9.PubMedGoogle Scholar
  158. 158.
    Nelles J, Fuhrer A, Vincenz I. Evaluation der HIV- und Hepatitis-Prophylaxe in der Kantonalen Anstalt Realta. Berne: Universitare Psychiatrische Dienste Bern; 1999.Google Scholar
  159. 159.
    Pintilei L. Harm reduction in prisons of Republic of Moldova. Ukraine: Kiev; 2005.Google Scholar
  160. 160.
    Dolan KA, Wodak AD, Hall WD. Methadone maintenance treatment reduces heroin injection in New South Wales prisons. Drug Alcohol Rev. 1998;17(2):153–8.PubMedCrossRefGoogle Scholar
  161. 161.
    Dolan KA, Shearer J, MacDonald M, Mattick RP, Hall W, Wodak AD. A randomised controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system. Drug Alcohol Depend. 2003;72(1):59–65.PubMedCrossRefGoogle Scholar
  162. 162.
    Boguna J. Methadone maintenance programmes. In: O’Brien O, editor. Report of the 3rd European Conference on Drug and HIV/AIDS Services in Prison. London: Cranstoun Drug Services; 1997. p. 68–70.Google Scholar
  163. 163.
    Heimer R, Catania H, Newman RG, Zambrano J, Brunet A, Ortiz AM. Methadone maintenance in prison: evaluation of a pilot program in Puerto Rico. Drug Alcohol Depend. 2006;83(2):122–9.PubMedCrossRefGoogle Scholar
  164. 164.
    Larney S. Does opioid substitution treatment in prisons reduce injecting-related HIV risk behaviours? A systematic review. Addiction. 2010;105(2):216–23.PubMedCrossRefGoogle Scholar
  165. 165.
    Hagan H, Des J, Stern R, et al. HCV synthesis project: preliminary analyses of HCV prevalence in relation to age and duration of injection. Int J Drug Policy. 2007;18(5):341–51.PubMedCrossRefGoogle Scholar
  166. 166.
    Vickerman P, Hickman M, May M, Kretzschmar M, Wiessing L. Can hepatitis C virus prevalence be used as a measure of injection-related human immunodeficiency virus risk in populations of injecting drug users? An ecological analysis. Addiction. 2010;105(2):311–8.PubMedCrossRefGoogle Scholar
  167. 167.
    Edlin BR, Kresina TF, Raymond DB, et al. Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis. 2005;40 Suppl 5:S276–85.PubMedCrossRefGoogle Scholar
  168. 168.
    Mateu-Gelabert P, Treloar C, Calatayud VA, et al. How can hepatitis C be prevented in the long term? Int J Drug Policy. 2007;18(5):338–40.PubMedCrossRefGoogle Scholar
  169. 169.
    Edlin BR. Prevention and treatment of hepatitis C in injection drug users. Hepatology. 2002;36 (5 Suppl 1):S210–9.PubMedCrossRefGoogle Scholar
  170. 170.
    Rottingen JA, Cameron DW, Garnett GP. A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: how much really is known? Sex Transm Dis. 2001;28(10):579–97.PubMedCrossRefGoogle Scholar
  171. 171.
    Cohen MS. HIV and sexually transmitted diseases: lethal synergy. Top HIV Med. 2004;12(4):104–7.PubMedGoogle Scholar
  172. 172.
    Institute of Medicine. The Hidden Epidemic: Confronting Sexually Transmitted Diseases. Washington, DC: National Academy Press; 1997.Google Scholar
  173. 173.
    Hayes R, Watson-Jones D, Celum C, van de Wasserheit J. Treatment of sexually transmitted infections for HIV prevention: end of the road or new beginning? AIDS. 2010;24 Suppl 4:S15–26.PubMedCrossRefGoogle Scholar
  174. 174.
    Miller M, Liao Y, Wagner M, Korves C. HIV, the clustering of sexually transmitted infections, and sex risk among African American women who use drugs. Sex Transm Dis. 2008;35(7):696–702.PubMedCrossRefGoogle Scholar
  175. 175.
    Jin F, Prestage GP, Matthews G, et al. Prevalence, incidence and risk factors for hepatitis C in homosexual men: data from two cohorts of HIV-negative and HIV-positive men in Sydney, Australia. Sex Transm Infect. 2010;86(1):25–8.PubMedCrossRefGoogle Scholar
  176. 176.
    Tyndall MW, Patrick D, Spittal P, Li K, O’Shaughnessy MV, Schechter MT. Risky sexual behaviours among injection drugs users with high HIV prevalence: implications for STD control. Sex Transm Infect. 2002;78 Suppl 1:i170–5.PubMedCrossRefGoogle Scholar
  177. 177.
    Wasserheit JN, Aral SO. The dynamic topology of sexually transmitted disease epidemics: implications for prevention strategies. J Infect Dis. 1996;174 Suppl 2:S201–13.PubMedCrossRefGoogle Scholar
  178. 178.
    Grosskurth H, Mosha F, Todd J, et al. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet. 1995;346(8974):530–6.PubMedCrossRefGoogle Scholar
  179. 179.
    Aral SO, Holmes KK. Social and behavioral determinants of the epidemiology of STDs: Industrialized and developing countries. In: Holmes KK, Sparling PF, Mardh P, Lemon SM, Stamm WE, Piot P, et al., editors. Sexually transmitted diseases. 3rd ed. New York: McGraw-Hill; 1999. p. 39–76.Google Scholar
  180. 180.
    Semaan S, Des J, Sogolow E, et al. A meta-analysis of the effect of HIV prevention interventions on the sex behaviors of drug users in the United States. J Acquir Immune Defic Syndr. 2002;30 Suppl 1:S73–93.PubMedGoogle Scholar
  181. 181.
    Blankenship KM, Friedman SR, Dworkin S, Mantell JE. Structural interventions: concepts, challenges and opportunities for research. J Urban Health. 2006;83(1):59–72.PubMedCrossRefGoogle Scholar
  182. 182.
    Lally MA, Alvarez S, Macnevin R, et al. Acceptability of sexually transmitted infection screening among women in short-term substance abuse treatment. Sex Transm Dis. 2002;29(12):752–5.PubMedCrossRefGoogle Scholar
  183. 183.
    Mimiaga MJ, Safren SA, Dvoryak S, Reisner SL, Needle R, Woody G. “We fear the police, and the police fear us”: structural and individual barriers and facilitators to HIV medication adherence among injection drug users in Kiev, Ukraine. AIDS Care. 2010;22(11):1305–13.PubMedCrossRefGoogle Scholar
  184. 184.
    Blankenship KM, Koester S. Criminal law, policing policy, and HIV risk in female street sex workers and injection drug users. J Law Med Ethics. 2002; 30(4):548–59.PubMedCrossRefGoogle Scholar
  185. 185.
    Wright-De AL, Weinstein B, Jones TS, Miles J. Impact of the change in Connecticut syringe prescription laws on pharmacy sales and pharmacy managers’ practices. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18 Suppl 1:S102–10.CrossRefGoogle Scholar
  186. 186.
    Open Society Institute. Harm Reduction: Public Health and Public Order. International Harm Reduction Development Program; 2007 Oct.Google Scholar
  187. 187.
    The Reference Group to the UN of HIV and Injection Drug Use. Consensus Statement of the Reference Group to the United Nations on HIV and Injecting Drug Use. 2010.Google Scholar
  188. 188.
    Des Jaralis DC, Semaan S. HIV and other sexually transmitted infections in injection drug users and crack cocaine smokers. In: Holmes KK, Sparling PF, Stamm WE, Piot P, Wasserheit JN, Corey L, et al., editors. Sexually transmitted diseases. 4th ed. New York: McGraw-Hill; 2008. p. 237–55.Google Scholar
  189. 189.
    Gebo KA, Keruly J, Moore RD. Association of social stress, illicit drug use, and health beliefs with nonadherence to antiretroviral therapy. J Gen Intern Med. 2003;18(2):104–11.PubMedCrossRefGoogle Scholar
  190. 190.
    Chander G, Himelhoch S, Moore RD. Substance abuse and psychiatric disorders in HIV-positive patients: epidemiology and impact on antiretroviral therapy. Drugs. 2006;66(6):769–89.PubMedCrossRefGoogle Scholar
  191. 191.
    Gunn RA, Murray PJ, Ackers ML, Hardison WG, Margolis HS. Screening for chronic hepatitis B and C virus infections in an urban sexually transmitted disease clinic: rationale for integrating services. Sex Transm Dis. 2001 March;28(3):166–70.CrossRefGoogle Scholar
  192. 192.
    Latkin CA, Knowlton RA. Micro-social structural approaches to HIV prevention: A social ecological perspective. AIDS Care. 2005;17 Suppl 1:S102–13.PubMedCrossRefGoogle Scholar
  193. 193.
    Cottrell CA, Neuberg SL. Different emotional reactions to different groups: A sociofunctional threat-based approach to “prejudice”. J Pers Soc Psychol. 2005;88(5):770–89.PubMedCrossRefGoogle Scholar
  194. 194.
    Sylla L, Bruce RD, Kamarulzaman A, Altice FL. Integration and co-location of HIV/AIDS, tuberculosis and drug treatment services. Int J Drug Policy. 2007;18(4):306–12.PubMedCrossRefGoogle Scholar
  195. 195.
    Sylvestre DL, Zweben JE. Integrating HCV services for drug users: a model to improve engagement and outcomes. Int J Drug Policy. 2007;18(5):406–10.PubMedCrossRefGoogle Scholar
  196. 196.
    Birkhead GS, Klein SJ, Candelas AR, et al. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach. Int J Drug Policy. 2007;18(5):417–25.PubMedCrossRefGoogle Scholar
  197. 197.
    Hennessy RR, Weisfuse IB, Schlanger K. Does integrating viral hepatitis services into a public STD clinic attract injection drug users for care? Public Health Rep. 2007;122 Suppl 2:31–5.PubMedGoogle Scholar
  198. 198.
    Keeny E, Saucier R. Lowering the threshold: Models of accessible methadone and buprenorphine treatment. New York: Open Society Institute; 2010.Google Scholar
  199. 199.
    Zhao M, Du J, Lu GH, et al. HIV sexual risk behaviors among injection drug users in Shanghai. Drug Alcohol Depend. 2006;82 Suppl 1:S43–7.PubMedCrossRefGoogle Scholar
  200. 200.
    U.S. Office of National Drug Control Policy. National Drug Control Strategy. 2010.Google Scholar
  201. 201.
    U.S. Office of National AIDS Policy. Nation HIV/AIDS Strategy for the United States. 2010.Google Scholar
  202. 202.
    PEPFAR. Comprehensive HIV prevention for people who inject drugs, revised guidance. 2010.Google Scholar
  203. 203.
    Sharma M, Oppenheimer E, Saidel T, Loo V, Garg R. A situation update on HIV epidemics among people who inject drugs and national responses in South-East Asia Region. AIDS. 2009;23(11):1405–13.PubMedCrossRefGoogle Scholar
  204. 204.
    World Health Organization, UNODC, UNAIDS. WHO, UNODC, UNAIDS technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users. Geneva: WHO/UNAIDS/UNODC; 2009.Google Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Office of the Global Aids CoordinatorWashingtonUSA
  2. 2.Division of Global HIVAIDSU.S. Centers for Disease Control and PreventionAtlantaUSA
  3. 3.HIV DepartmentWorld Health OrganizationGeneva 27Switzerland

Personalised recommendations